ALKERMES | ALKS - 销售收入

金融业

USD

USD 4.26B

现金及等价物

USD 351.55M

USD 73.25M

USD 1.36B

USD 599.5M

USD 1.58B

股息收益率

0

USD -48.28M

USD 80.26M

1.8K

EPS每股收益

USD -0.4

股本和储备

USD 1.75B

USD 331.33M

债务利息支出

USD 20.89M

USD 8.54M

USD 1.48B

USD 7.2B

USD -66.48M

USD 1.75B

USD -48.28M

普通股股本

USD 166.46M

39.33

USD -61.93M

USD 392.91M

销售和管理费用

USD 264.59M

USD 336.7M

贸易债权人

USD 102.36M

应收帐款人

USD 407.63M

	销售	更改		日
AbbVie	USD 15B		1.62B	2026-03
Acadia Pharmaceuticals	USD 268.06M		15.94M	2026-03
ALKERMES	USD 392.91M		8.41M	2026-03
Amgen	USD 8.62B		1.28B	2026-03
Biogen	USD 2.25B		30M	2026-03
BioMarin Pharmaceutical	USD 766M		109M	2026-03
Bristol-Myers Squibb	USD 11.49B		1.01B	2026-03
Coherus Biosciences	USD 12.75M		1.18M	2025-12
Eli Lilly	USD 19.8B		500M	2026-03
Gilead Sciences	USD 7B		930M	2026-03
Heron Therapeutics	USD 40.59M		2.38M	2025-12
Ionis Pharmaceuticals	USD 246M		43M	2026-03
J&J	USD 24.1B		500M	2026-03
Merck	USD 16.29B		110M	2026-03
Minerva Neurosciences	USD 0		0	2024-09
Nektar Therapeutics	USD 21.81M		2.32M	2025-12
Neurocrine Biosciences	USD 811M		5.5M	2026-03
Otsuka Holdings	JPY 630.34B		19.81B	2026-03
Pfizer	USD 14.5B		3.08B	2026-03
Regeneron Pharmaceuticals	USD 3.6B		280M	2026-03
Vertex Pharmaceuticals	USD 2.99B		200M	2026-03